• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    Cholesterol
    Information
    CAS No. 57-88-5 Price $30 / 20mg
    Catalog No.CFN90040Purity>=98%
    Molecular Weight386.67Type of CompoundSteroids
    FormulaC27H46OPhysical DescriptionPowder
    Download     COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Chungnam National University (Korea)
  • Monash University (Australia)
  • Universidad de La Salle (Mexico)
  • Agricultural Research Organizati... (Israel)
  • Sapienza University of Rome (Italy)
  • Shanghai University of TCM (China)
  • MTT Agrifood Research Finland (Finland)
  • Seoul National University of Sci... (Korea)
  • Uniwersytet Medyczny w ?odzi (Poland)
  • Martin Luther University of Hall... (Germany)
  • University of Padjajaran (Indonesia)
  • More...
  • Package
    Featured Products
    20-Deoxocarnosol

    Catalog No: CFN92175
    CAS No: 94529-97-2
    Price: $463/5mg
    Isoacteoside

    Catalog No: CFN97049
    CAS No: 61303-13-7
    Price: $178/20mg
    Isofebrifugine

    Catalog No: CFN92303
    CAS No: 32434-44-9
    Price: $588/10mg
    Morusinol

    Catalog No: CFN97086
    CAS No: 62949-93-3
    Price: $388/5mg
    Cimicidanol 3-O-alpha-L-arabinoside

    Catalog No: CFN90863
    CAS No: 161207-05-2
    Price: $268/20mg
    Biological Activity
    Description: Cholesterol, a major eukaryotic lipid, can markedly modulate protein dynamics.The liposomal single-molecule approach highlighted the significance of the Cholesterol-induced basal force for interhelical interactions, which will aid discussions of complex protein-membrane systems.Cholesterol trafficking as an attractive therapeutic target for cancer treatment.
    Targets: VEGFR | mTOR
    In vivo:
    Am J Med. 2015 Apr;128(4):403-9.
    Cholesterol treatment and changes in guidelines in an academic medical practice.[Pubmed: 25460526]
    National guidelines are intended to influence physician Cholesterol treatment practices, yet few studies have documented the effect of new guidelines on actual prescribing behaviors and impacts on patient eligibility for treatment. We describe current Cholesterol treatment in an academic practice of Family and Internal Medicine physicians as well the effect of a change in Cholesterol treatment guidelines from 2001 Adult Treatment Panel III (ATPIII) to 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines.
    METHODS AND RESULTS:
    Medical records were extracted from primary care patients aged 40-75 years with at least one outpatient visit from January 1, 2012 to July 31, 2013; patients were included if they had records of Cholesterol testing, blood pressure measurement, sex, race, and smoking status. Patients were classified into ATPIII and ACC/AHA categories based on clinical variables (eg, diabetes, hypertension, atherosclerotic cardiovascular disease), Framingham Risk Score, and 10-year atherosclerotic cardiovascular disease risk. There were 4536 patients included in the analysis. Of these, 71% met ATPIII goals and 56% met ACC/AHA guidelines, a 15% decrease. Forty-three percent of high-risk patients met their low-density lipoprotein goals and 46% were on statins. Overall, 32% of patients would need to be started on a statin, 12% require an increased dose, and 6% could stop statins. Of patients considered low risk by ATPIII guidelines, 271 would be eligible for treatment by ACC/AHA guidelines, whereas 129 patients were shifted from intermediate risk to low risk with the change in guidelines.
    CONCLUSIONS:
    The ACC/AHA guidelines expand the number of patients recommended to receive statins, particularly among patients who were previously thought to be at moderate risk, and would increase the intensity of treatment for many patients at high risk. Significant numbers of patients at risk for cardiovascular events were not receiving guideline-based treatment. New Cholesterol guidelines may make treatment decisions easier.
    Biochem Biophys Res Commun. 2015 Feb 20;457(4):614-20.
    Cholesterol reduces the sensitivity to platinum-based chemotherapy via upregulating ABCG2 in lung adenocarcinoma.[Pubmed: 25603057]
    Inoperable lung adenocarcinoma is currently treated with platinum-based chemotherapy. However, the effectiveness of these chemotherapeutic agents is not the same for all patients.
    METHODS AND RESULTS:
    Patients either show quick chemoresistance (QCR) or delayed chemoresistance (DCR), which are defined by 87 and 242 days of progression-free survival (PFS) after initial platinum-based treatment, respectively. We found that QCR patients displayed an elevated level of serum Cholesterol and that their tumors showed upregulated ABCG2 expression. We propose that chemoresistance may be attributed to Cholesterol-induced ABCG2 expression and hypothesize that blocking ABCG2 may increase the efficacy of platinum-based chemotherapeutic agents. Using the MTT cell viability assay, we observed that cotreatment with ABCG2 blocker Nicardipine and platinum-based drugs Cisplatin, Oxaliplatin or Carboplatin significantly decreased cell viability of tumor cells.
    CONCLUSIONS:
    Importantly, our results also showed that incubating cells with Cholesterol prior to chemotherapy treatment or cotreatment increased cell viability of tumor cells relative to the controls.
    Cholesterol Description
    Source: The leaves of Olea europaea L.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    Tenuifoliside A

    Catalog No: CFN90770
    CAS No: 139726-35-5
    Price: $278/20mg
    6-Methoxywogonin

    Catalog No: CFN98403
    CAS No: 3162-45-6
    Price: $368/5mg
    Cryptochlorogenic acid

    Catalog No: CFN99117
    CAS No: 905-99-7
    Price: $128/20mg
    Ganoderic acid C2

    Catalog No: CFN92054
    CAS No: 103773-62-2
    Price: $660/10mg
    Cassiaside C

    Catalog No: CFN95120
    CAS No: 119170-52-4
    Price: $318/5mg
    Yangambin

    Catalog No: CFN96416
    CAS No: 13060-14-5
    Price: $398/5mg
    3,4-O-dimethylcedrusin

    Catalog No: CFN95026
    CAS No: 166021-14-3
    Price: $388/10mg
    Betmidin

    Catalog No: CFN95047
    CAS No: 35589-22-1
    Price: $413/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.
    doi:10.1016/j.phymed.2017.12.030

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.5862 mL 12.9309 mL 25.8618 mL 51.7237 mL 64.6546 mL
    5 mM 0.5172 mL 2.5862 mL 5.1724 mL 10.3447 mL 12.9309 mL
    10 mM 0.2586 mL 1.2931 mL 2.5862 mL 5.1724 mL 6.4655 mL
    50 mM 0.0517 mL 0.2586 mL 0.5172 mL 1.0345 mL 1.2931 mL
    100 mM 0.0259 mL 0.1293 mL 0.2586 mL 0.5172 mL 0.6465 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Protocol
    Kinase Assay:
    Cancer Lett. 2015 Jun 28;362(1):106-15.
    Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism.[Pubmed: 25799952]
    Selective estrogen receptor modulators (SERM) including tamoxifen are known to inhibit angiogenesis. However, the underlying mechanism, which is independent of their action on the estrogen receptor (ER), has remained largely unknown.
    METHODS AND RESULTS:
    In the present study, we found that tamoxifen and other SERM inhibited Cholesterol trafficking in endothelial cells, causing a hyper-accumulation of Cholesterol in late endosomes/lysosomes. Inhibition of Cholesterol trafficking by tamoxifen was accompanied by abnormal subcellular distribution of vascular endothelial growth factor receptor-2 (VEGFR2) and inhibition of the terminal glycosylation of the receptor. Tamoxifen also caused perinuclear positioning of lysosomes, which in turn trapped the mammalian target of rapamycin (mTOR) in the perinuclear region of endothelial cells. Abnormal distribution of VEGFR2 and mTOR and inhibition of VEGFR2 and mTOR activities by tamoxifen were significantly reversed by addition of Cholesterol-cyclodextrin complex to the culture media of endothelial cells. Moreover, high concentrations of tamoxifen inhibited endothelial and breast cancer cell proliferation in a Cholesterol-dependent, but ER-independent, manner.
    CONCLUSIONS:
    Together, these results unraveled a previously unrecognized mechanism of angiogenesis inhibition by tamoxifen and other SERM, implicating Cholesterol trafficking as an attractive therapeutic target for cancer treatment.
    Structure Identification:
    Biochemistry. 2015 Feb 17;54(6):1371-9.
    Cholesterol-induced lipophobic interaction between transmembrane helices using ensemble and single-molecule fluorescence resonance energy transfer.[Pubmed: 25629582]
    The solvent environment regulates the conformational dynamics and functions of solvated proteins. In cell membranes, Cholesterol, a major eukaryotic lipid, can markedly modulate protein dynamics.
    METHODS AND RESULTS:
    To investigate the nonspecific effects of Cholesterol on the dynamics and stability of helical membrane proteins, we monitored association-dissociation dynamics on the antiparallel dimer formation of two simple transmembrane helices (AALALAA)3 with single-molecule fluorescence resonance energy transfer (FRET) using Cy3B- and Cy5-labeled helices in lipid vesicles (time resolution of 17 ms). The incorporation of 30 mol % Cholesterol into phosphatidylcholine bilayers significantly stabilized the helix dimer with average lifetimes of 450-170 ms in 20-35 °C. Ensemble FRET measurements performed at 15-55 °C confirmed the Cholesterol-induced stabilization of the dimer (at 25 °C, ΔΔG(a) = -9 kJ mol(-1) and ΔΔHa = -60 kJ mol(-1)), most of which originated from "lipophobic" interactions by reducing helix-lipid contacts and the lateral pressure in the hydrocarbon core region. The temperature dependence of the dissociation process (activation energy of 48 kJ) was explained by the Kramers-type frictional barrier in membranes without assuming an enthalpically unfavorable transition state. In addition to these observations, Cholesterol-induced tilting of the helices, a positive ΔC(p(a)), and slower dimer formation compared with the random collision rate were consistent with a hypothetical model in which Cholesterol stabilizes the helix dimer into an hourglass shape to relieve the lateral pressure.
    CONCLUSIONS:
    Thus, the liposomal single-molecule approach highlighted the significance of the Cholesterol-induced basal force for interhelical interactions, which will aid discussions of complex protein-membrane systems.